Darolutamide With ADT/Docetaxel Shows Reduced Risk of Death in mHSPC Irrespective of Age
The Promising Future of Prostate Cancer Treatment: Darolutamide Shows Hope Recent findings from the 2025 Genitourinary Cancers Symposium highlighted darolutamide’s (brand name Nubeqa) significant impact on managing metastatic hormone-sensitive prostate cancer (mHSPC). In combination with androgen deprivation therapy (ADT) and docetaxel, this trio demonstrates a noteworthy decrease in death risk compared to standard placebo treatments, … Read more